战略委员会议事规则 亿帆医药股份有限公司 YIFAN PHARMACEUTICAL CO.,LTD. 战略委员会议事规则 （二 O 二五年八月修订） 战略委员会议事规则 目 录 战略委员会议事规则 第一章 总 则 第一条 为适应公司战略发展需要，增强公司核心竞争力，确定公司发展规 划，健全投资决策程序，加强决策科学性，提高重大投资决策的效益和决策的质 量，完善公司的治理机构，根据《中华人民共和国公司法》 （以下简称"《公司法》"） 《上市公司治理准则》 《上市公司独立董事管理办法》 《亿帆医药股份有限公司章 程》 （以下简称"《公司章程》"）及其他有关规定，公司特设立董事会战略委员会 （以下简称"战略委员会"），并制定本议事规则。 第二条 董事会战略委员会是董事会按照股东会决议设立的专门工作机构， 主要负责对公司长期发展战略和重大投资决策进行研究并提出建议。 第二章 人员组成 第三条 战略委员会成员由五名董事组成，其中应至少包括二名独立董事。 第四条 战略委员会委员由董事会选举并由全体董事的过半数通过产生。 第五条 战略委员会设召集人一名，由公司董事长担任。 第六条 《公司法》《公司章程》关于董事的任职资格和 ...

董事会秘书工作细则 亿帆医药股份有限公司 YIFAN PHARMACEUTICAL CO.,LTD. 董事会秘书工作细则 （二 O 二五年八月修订） 董事会秘书工作细则 目 录 董事会秘书工作细则 第一章 总 则 第一条 为进一步规范亿帆医药股份有限公司（以下简称"公司"）董事 会秘书的工作职责和程序，加强对董事会秘书工作的管理与监督，充分发挥董 事会秘书的作用，根据《中华人民共和国公司法》（以下简称"《公司法》"） 《中华人民共和国证券法》《深圳证券交易所股票上市规则》《上市公司自律 监管指引第1号—主板上市公司规范运作》等有关法律法规、规范性文件及《亿 帆医药股份有限公司章程》（以下简称"《公司章程》"）的相关规定，特制 定本工作细则。 第二条 公司设董事会秘书一名，作为公司与深圳证券交易所（以下简称 "深交所"）之间的指定联络人，董事会秘书为公司高级管理人员，对公司和 董事会负责，承担法律、法规及《公司章程》对公司高级管理人员所要求的义 务，享有相应的工作职权，并获取相应报酬。 第三条 董事会秘书对公司负有忠实和勤勉义务，不得利用职权为自己或 他人谋取利益。 第四条 公司设董事会秘书处，由董事会秘书负责 ...

薪酬与考核委员会议事规则 亿帆医药股份有限公司 YIFAN PHARMACEUTICAL CO.,LTD. 薪酬与考核委员会议事规则 （二 O 二五年八月修订） 酬与考核委员会议事规则 目 录 薪酬与考核委员会议事规则 第一章 总则 第一条 为进一步建立健全公司董事（非独立董事）及高级管理人员（以下 简称高管人员）的考核和薪酬管理制度，完善公司治理结构，根据《中华人民共 和国公司法》（以下简称"《公司法》"）《深圳证券交易所上市公司自律监管指引 第 1 号—主板上市公司规范运作》 《上市公司治理准则》 《上市公司独立董事管理 办法》 《亿帆医药股份有限公司章程》（以下简称"《公司章程》"）及其他有关规 定，公司特设董事会薪酬与考核委员会（以下简称"薪酬与考核委员会"），并制 订本议事规则。 第二条 薪酬与考核委员会是董事会按照股东会决议设立的专门工作机构， 负责制定董事、高级管理人员的考核标准并进行考核，制定、审查董事、高级管 理人员的薪酬政策与方案，对董事会负责。 第三条 本议事规则所称的高管人员是指董事会聘任的总裁、执行总裁、高 级副总裁、副总裁、财务总监、董事会秘书及由总裁提请董事会认定的其他高级 管理 ...

审计委员会议事规则 亿帆医药股份有限公司 YIFAN PHARMACEUTICAL CO.,LTD. 审计委员会议事规则 （二 O 二五年八月修订） 会议事规则 目 录 审计委员会议事规则 第一章 总 则 本议事规则。 第二条 董事会审计委员会是董事会按照股东会决议设立的专门工作机构， 行使《公司法》规定的监事会的职权。审计委员会应当负责审核公司财务信息及 其披露、监督及评估内外部审计工作和内部控制。 第二章 人员组成 第三条 审计委员会成员由 3 名以上不在上市公司担任高级管理人员的董 事组成，其中独立董事应当过半数，董事会成员中的职工代表可以成为审计委员 会成员。委员中至少有一名独立董事为会计专业人士。审计委员会成员应当具备 胜任工作职责的专业知识、工作经验和良好的职业操守，保证足够的时间和精力 履行委员会的工作职责。 第四条 审计委员会委员由董事会选举并由全体董事的过半数通过产生。 第五条 审计委员会设召集人一名，由独立董事担任，负责主持委员会工作； 召集人应当为会计专业人士，由董事会直接在委员内选举产生。 第六条 《公司法》《公司章程》关于董事的任职资格和义务规定适用于审 计委员会委员。 第七条 审计 ...

《上市公司股东会规则》 《上市公司独立董事管理办法》 《上市公司治理准则》 股东会议事规则 亿帆医药股份有限公司 YIFAN PHARMACEUTICAL CO.,LTD. 股东会议事规则 （二 O 二五年八月修订） 股东会议事规则 目 录 股东会议事规则 第一章 总 则 第一条 为规范公司行为，保证本公司股东会依法行使职权，维护本公司和 股东的合法权益，根据《中华人民共和国公司法》（以下简称"《公司法》"） 《中华人民共和国证券法》 （以下简称"《证券法》"）、 《深圳证券交易所股票上市 规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运 作》等法律、行政法规、规范性文件以及本公司章程的规定，制订本规则。 第二条 公司股东会的召集、提案、通知、召开等事项适用本规则。 第三条 公司应当严格按照法律、行政法规、本规则及公司章程的相关规定 召开股东会，保证股东能够依法行使权利。 公司董事会应当切实履行职责，认真、按时组织股东会。公司全体董事应当 勤勉尽责，确保股东会正常召开和依法行使职权。 第四条 股东会应当在《公司法》和公司章程规定的范围内行使职权。 第五条 股东会分为年度股东会和临时股 ...

Core Viewpoint - Yifan Pharmaceutical Co., Ltd. reported a slight increase in revenue and a significant rise in net profit for the first half of 2025, driven by innovative drug sales and operational efficiency improvements [2][3][12]. Company Overview - Yifan Pharmaceutical is a publicly listed company on the Shenzhen Stock Exchange, specializing in the research, development, production, and sales of pharmaceutical products, including biological drugs, chemical drugs, and traditional Chinese medicine [2][3]. - The company has a strong international presence, with products approved for sale in over 50 countries, including China, the USA, the EU, and Brazil [8][9]. Financial Performance - The company achieved operating revenue of approximately CNY 2.635 billion in the first half of 2025, a 0.11% increase year-on-year [3][12]. - Net profit attributable to shareholders was CNY 237.21 million, reflecting a 32.21% increase compared to the previous year [3][12]. - The basic earnings per share rose to CNY 0.25, a 19.05% increase from the previous period [3][12]. Business Segments - The main business activities include the development and sales of pharmaceutical products, vitamins, and high polymer materials [3][12]. - The company’s innovative drug, Yili Shu (艾贝格司亭 α), has been successfully commercialized in multiple international markets, marking a significant milestone for the company [13][14]. Market Position - Yifan Pharmaceutical holds a leading position in the vitamin B5 market, with over 70% of its sales directed towards international markets, particularly in Europe and North America [6][9]. - The company is recognized for its unique products, including those listed in the World Health Organization's essential medicines list, and has a robust pipeline of innovative drugs [8][11]. Industry Context - The pharmaceutical industry in China is undergoing significant transformation, with a shift towards innovative drugs amid pressures on traditional generic markets [6][7]. - The vitamin industry is experiencing structural changes, with increased competition and a focus on technological advancements to enhance product offerings [6][7]. Strategic Initiatives - The company is actively pursuing global expansion strategies, focusing on brand development and channel integration to enhance its market presence [17][18]. - Ongoing projects include the development of new drug candidates and the establishment of international research and production facilities to support its growth objectives [16][17].

Core Viewpoint - Yifan Pharmaceutical Co., Ltd. reported a slight increase in revenue and a significant rise in net profit for the first half of 2025, indicating strong operational performance and growth in innovative drug sales [2][6]. Financial Performance - The company's operating income for the reporting period was approximately CNY 2.635 billion, a year-on-year increase of 0.11% [2][6]. - Net profit attributable to shareholders reached approximately CNY 303.65 million, reflecting a year-on-year growth of 19.91% [2][6]. - The net profit after deducting non-recurring gains and losses was approximately CNY 237.21 million, up 32.21% year-on-year [6][10]. - Basic earnings per share increased to CNY 0.25, a rise of 19.05% compared to the previous year [2][3]. Business Highlights - Revenue from pharmaceutical-related operations was approximately CNY 2.254 billion, accounting for 85.53% of total revenue, with innovative drugs Yilishu and Yinikang showing a combined sales increase of 169.57% [6][10]. - The company successfully launched its first self-developed Class I macromolecule innovative biological drug, Yilishu, in the U.S. market, with a terminal price of USD 4,600 per unit [7][10]. - Yilishu has been approved for sale in 34 countries/regions and has achieved sales in five countries, with ongoing regulatory applications in Thailand, the Philippines, Malaysia, and the UAE [7][9]. Strategic Developments - The company established a global business development center to enhance international market expansion and collaboration [11][12]. - Yifan Pharmaceutical is focusing on the commercialization of Yilishu and optimizing costs, with significant partnerships established across over 40 countries [7][10]. - The company is advancing its research and development efforts, with several new drug applications submitted and clinical trials approved for various products [13][14]. Market Position - The company’s overseas pharmaceutical formulations generated revenue of approximately CNY 331.99 million, a year-on-year increase of 6.46% [10][11]. - Domestic pharmaceutical sales reached approximately CNY 1.921 billion, reflecting a growth of 3.57% year-on-year, driven by product matrix optimization and marketing strategy upgrades [10][11].

Core Points - The company held its 18th meeting of the 8th Board of Directors, where all 8 directors participated and approved several key resolutions [1][2][3] Meeting Details - The meeting was convened in accordance with the Company Law and the Articles of Association, ensuring compliance with relevant regulations [1] - All resolutions were passed with unanimous support, with 8 votes in favor and no votes against or abstentions [2][3] Financial Reports - The Board approved the 2025 Half-Year Report and its summary, which will be disclosed on the company's official information platform [1] Board Elections - The Board approved the nomination of candidates for the 9th Board of Directors, including non-independent directors and independent directors, with all candidates receiving unanimous support [2][3] Amendments to Company Regulations - Several amendments to the company's internal regulations were approved, including revisions to the Articles of Association, Shareholders' Meeting Rules, and Board Meeting Rules [4][5][6] - The company also approved changes to the Independent Director Work System and the Management of Raised Funds [5][6] Independent Director Compensation - The Board approved an increase in the compensation for independent directors from RMB 100,000 to RMB 150,000 per year, reflecting the company's operational context and market conditions [6][7] Upcoming Shareholder Meeting - The Board resolved to convene the second extraordinary general meeting of shareholders in 2025 to discuss the approved resolutions [8]

证券代码：002019 证券简称：亿帆医药 公告编号：2025-045 亿帆医药股份有限公司 第八届监事会第十五次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 经审核，监事会认为：公司董事会编制和审核《2025 年半年度报告》和《2025 年半年度报告摘要》的程序符合法律、行政法规和中国证监会的规定，报告内容 真实、准确、完整地反映了公司的实际情况，不存在任何虚假记载、误导性陈述 或者重大遗漏。 三、备查文件 亿帆医药股份有限公司监事会 《第八届监事会第十五次会议决议》 一、监事会会议召开情况 亿帆医药股份有限公司（以下简称"公司"）第八届监事会第十五次会议于 公司一楼会议室召开。会议由监事会主席许国汉先生主持，会议应参加表决的监 事 3 人，实际参加表决的监事 3 人。会议的召开符合《公司法》和《公司章程》 的相关规定，会议合法有效。 二、监事会会议审议情况 特此公告。 经全体监事认真审议，会议以投票表决的方式形成以下决议： （一）会议以 3 票同意、0 票反对、0 票弃权的结果，审议通过了《公司 2025 年半年度报告及其摘要》 ...

Financial Overview - The total assets of Yifan Pharmaceutical Co., Ltd. increased from CNY 12,285,788,088.75 at the beginning of the period to CNY 12,674,139,895.70 at the end, representing a growth of approximately 3.17% [1][2] - Total liabilities rose from CNY 3,858,992,750.77 to CNY 4,017,412,350.66, indicating an increase of about 4.1% [2][3] - The total equity increased from CNY 8,426,795,337.98 to CNY 8,656,727,545.04, reflecting a growth of approximately 2.72% [2][3] Income Statement Highlights - The total operating revenue for the first half of 2025 was CNY 2,635,110,083.18, slightly up from CNY 2,632,089,783.35 in the same period of 2024 [3][4] - Total operating costs decreased from CNY 2,363,162,281.95 to CNY 2,316,453,207.97, showing a reduction of about 1.98% [4] - Net profit for the first half of 2025 was CNY 284,158,135.82, compared to CNY 212,445,979.23 in the first half of 2024, marking an increase of approximately 33.8% [4][5] Cash Flow Analysis - Net cash flow from operating activities improved significantly, rising from CNY 143,774,218.95 in the first half of 2024 to CNY 286,097,071.23 in the first half of 2025 [5] - Cash flow from investing activities showed a net outflow of CNY 159,041,410.09, compared to a larger outflow of CNY 195,466,241.92 in the previous year [5] - Cash flow from financing activities resulted in a net outflow of CNY 147,413,242.53, contrasting with a net inflow of CNY 207,793,148.58 in the first half of 2024 [5] Balance Sheet Insights - Current assets totaled CNY 3,967,724,843.29 at the end of the period, up from CNY 3,778,271,166.02 at the beginning, indicating a growth of approximately 5.03% [1][2] - Non-current assets increased from CNY 8,507,516,922.73 to CNY 8,706,415,052.41, reflecting a growth of about 2.34% [1][2] - The company's cash and cash equivalents decreased from CNY 889,388,507.75 to CNY 785,909,109.30, a decline of approximately 11.6% [1][2]